|
|
| Sunday September 4, 2022 |
| 13:30 | Registration |
|
| AGORA HALL |
| 16:00 | Opening Ceremony |
Dr Luc VAN HIJFTE (SYMERES, Nijmegen, The Netherlands)
Prof. Rebecca DEPREZ-POULAIN (INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)
Prof. Rui MOREIRA (UNIVERSITY OF LISBON, Lisbon, Portugal) |
| ATHENA AUDITORIUM |
| 16:20 | EFMC Fellows Ceremony |
Prof. Rui MOREIRA
(UNIVERSITY OF LISBON, Lisbon, Portugal) |
| 16:35 | Opening Lecture - Patient Testimonial |
|
| Chair |
Dr Tatjana ROSS
(MERCK HEALTHCARE KGAA, Darmstadt, Germany) |
| 16:50 | Musical Interlude |
|
| 17:00 | EFMC Awards Ceremony |
Prof. Rui MOREIRA
(UNIVERSITY OF LISBON, Lisbon, Portugal) |
| 17:20 | NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
AL001 - Pseudo Natural Products – Chemical Evolution of Natural Product Structure |
Prof. Herbert WALDMANN
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany) |
| Chairs |
Prof. Henk TIMMERMAN (VU UNIVERSITY AMSTERDAM, Oegstgeest, The Netherlands)
Dr Andele NAUTA (PROF. DR. W. TH NAUTA STICHTING, The Netherlands) |
| 18:05 | GDCh - Klaus Grohe Prize Ceremony |
|
| Laudatio |
|
| |
Prof. Herbert WALDMANN
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany) |
| Prize Ceremony |
|
| |
Dr Rolf ALBACH
(GDCH & COVESTRO, Cologne, Germany) |
| 18:15 | KLAUS GROHE PRIZE
PR001 - Discovery of a Druggable Copper-signaling Pathway that Drives Cell Plasticity and Inflammation |
Dr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France) |
| 19:00 | Welcome Reception sponsored by WuXi AppTec |
|
| RHODES HALL |
| 20:00 | End of the Day |
|
| Monday September 5, 2022 |
| 08:00 | Registration |
|
| AGORA HALL |
| 08:30 | UCB EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
AL002 - Small Molecule Drugs and where to find them - Approaches to Hit Generation and Lead Optimisation |
Prof. Mike WARING
(NEWCASTLE UNIVERSITY, Newcastle upon Tyne, United Kingdom) |
| ATHENA AUDITORIUM |
| Chair |
Dr Adrian HALL
(UCB BIOPHARMA SRL, Braine-l'Alleud, Belgium) |
| 09:15 | PL001 - Boosting « Chance and Necessity » with Experience and Molecular Creativity |
Prof. Benoit DEPREZ
(INSTITUT PASTEUR DE LILLE, Lille, France) |
| Chair |
Dr Luc VAN HIJFTE
(SYMERES, Nijmegen, The Netherlands) |
| 10:00 | Exhibition & Coffee |
|
| RHODES HALL |
Session 1 'Chemical Biology'
Beyond PROTACS, Monovalent and Glues Degraders | Session 2 'Drug Discovery'
Renaissance of Natural-Product Inspired Drug Discovery in the 21st Century | Session 3 'Technologies'
Methods for Late-Stage Functionalization
|
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 10:30 | Session Chair |
Dr Laura M. LUH
(BAYER, Wuppertal, Germany) |
|
| 10:30 | Session Chair |
Dr Boris VAUZEILLES
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France) |
|
| 10:30 | |
Prof. Tobias RITTER
(MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany) |
|
| 10:35 | LE001 - Strategies to Discover Molecular Glue Degraders at Scale |
Dr Cristina MAYOR-RUIZ
(IRB BARCELONA, Barcelona, Spain) |
|
| 10:35 | LE005 - Big Data Analyses for the Discovery of Lead Structures from Nature |
Prof. Judith ROLLINGER
(UNIVERSITY OF VIENNA, Vienna, Austria) |
|
|
| 11:15 | LE002 - Haven't Got a Glue: Protein Surface Variation for the Design of Molecular Glue Degraders |
Dr Nicolas THOMÄ
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
|
| 11:15 | LE006 - Design of Naturally Inspired Anti-Cancer Compounds that Modulate Cholesterol Homeostasis |
Dr Fanny ROUSSI
(ICSN - CNRS, Gif sur Yvette, France) |
|
| 11:15 | LE010 - Tritiation of Pharmaceuticals Via Late Stage C-H Functionalization |
Dr Dieter MURI
(ROCHE · PHARMA RESEARCH AND EARLY DEVELOPMENT (PRED), Basel, Switzerland) |
|
| 11:35 | LE003 - Antibody-Protac Conjugates: an Approach for Targeted Selective BRD4 Degradation in HER2+ Phenotypes |
Dr Maria MANEIRO
(UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain) |
|
| 11:35 | LE007 - Reduce to the Max: Functionally Optimized Natural Products via Chemical Synthesis
|
Prof. Karl GADEMANN
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland) |
|
| 11:35 | LE011 - Late-Stage Functionalizations |
Prof. Tobias RITTER
(MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany) |
|
| 11:55 | LE004 - Discovery And Profiling of AZ'6421: an Oral ERa-Protac with an in vitro-in vivo Disconnect |
Dr Thomas HAYHOW
(ASTRAZENECA, Cambridge, United Kingdom) |
|
| 11:55 | LE008 - Tuning the Reactivity of the Natural Product Andrographolide: Towards Targeted Covalent Inhibitors for the Treatment of Inflammation |
Prof. Christina CHAI
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore) |
|
| 11:55 | LE012 - Chemical Modification of Wild-type Proteins |
Dr Bauke ALBADA
(WUR, Wageningen, The Netherlands) |
|
|
| 12:15 | Exhibition & Lunch |
|
| RHODES HALL |
| 12:15 | Schrödinger workshop
Digital Chemistry in Action: Combining physics-based modelling, AI/ML and experimental data in
collaborative decision making |
|
| ROOM RISSO 8 |
| 12:15 | Mestrelab Research workshop
Automate your analytical workflows with Mnova
Gears: Relieve your teams from
long and tedious tasks! |
|
| ROOM RISSO 6 |
Flash Poster Session 1
FP01 to FP10
Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here
RHODES12 AUDITORIUM | Flash Poster Session 2
FP11 to FP20
Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here
ATHENA AUDITORIUM | Flash Poster Session 3
FP21 to FP30
Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here
HERMES AUDITORIUM |
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
|
|
|
|
|
Session 4 'Chemical Biology'
Targeting Epigenetic Modifications in Cancer Therapy / ICBS Session | Session 5 'Drug Discovery'
Drugging the Undruggable : Targeting Transcription Factors / ACSMEDI Session | Session 6 'Technologies'
Hit Discovery with DNA-Encoded Libraries
|
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 13:45 | Session Chair |
Prof. Zaneta NIKOLOVSKA-COLESKA
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States) |
|
| 13:45 | Session Chair |
Dr Anthony ROMERO
(ORIC PHARMACEUTICALS, South San Francisco, United States) |
|
| 13:45 | Session Chair |
Dr Andreas BRUNSCHWEIGER
(TU DORTMUND, Dortmund, Germany) |
|
| 13:50 | LE013 - Disrupting hDot1L and MLL Oncofusion Protein Interactions as a Novel Therapeutic Strategy
|
Prof. Zaneta NIKOLOVSKA-COLESKA
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States) |
|
| 13:50 | LE017 - Chemical Probe Discovery for Recalcitrant Targets
Virtual Presentation |
Prof. Angela KOEHLER
(MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States) |
|
| 13:50 | LE021 - Innovating DNA-encoded Chemical Library Technology for Better Ligand Discovery |
Dr Jörg SCHEUERMANN
(ETH ZURICH, Zürich, Switzerland) |
|
| 14:30 | LE014 - New Opportunities for Studying the Function of the Nucleosome Remodeling Factor, NURF, Through Inhibition and Degradation |
Prof. William POMERANTZ
(UNIVERSITY OF MINNESOTA, Minneapolis, United States) |
|
| 14:30 | LE018 - Transcription Factors as Drug-Discovery Targets |
Prof. Fraydoon RASTINEJAD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
|
| 14:30 | LE022 - A DNA Barcode with Enhanced Chemical Stability for DNA-encoded Library Design |
Dr Andreas BRUNSCHWEIGER
(TU DORTMUND, Dortmund, Germany) |
|
| 14:50 | LE015 - New Generation of EZH2 Inhibitors for Cancer Therapy: A Computer-Aided Drug Design Approach in Epigenetics |
Dr Filipa RAMILO-GOMES
(UNIVERSITY OF LISBON, Lisboa, Portugal) |
|
| 14:50 | LE019 - Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/Cyclin T1 for MYC-Dependent Cancers |
Dr David FREEMAN
(KRONOS BIO, INC. , Massachussetts, United States) |
|
| 14:50 | LE023 - Exploiting DNA-encoded Library Technology for the Discovery of Novel Antibody Recruiting Molecules Against LOX-1 |
Ms Katherine MACFARLANE
(UNIVERSITY OF STRATHCLYDE, London, United Kingdom) |
|
| 15:10 | EFMC-YMCS Prize 2021
LE016 - A Mating Mechanism to Generate Diversity for the Darwinian Selection of DNA-encoded Synthetic Molecules |
Mr Lluc FARRERA SOLER
(UNIVERSITY OF GENEVA, Geneva, Switzerland) |
|
| 15:10 | LE020 - Inhibiting the MYC Oncogene through Cell Active Max-E47 (ME-47) |
Dr Amy BITTNER MCCRACKEN
(MSD, New Jersey, United States) |
|
| 15:10 | LE024 - Photoactivated Covalent Capture of DNA-encoded Fragments to Identify Ligands for Challenging Targets |
Prof. Roderick HUBBARD
(VERNALIS, Cambridge, United Kingdom) |
|
|
| 15:30 | Exhibition & Coffee |
|
| RHODES HALL |
| SCT (Société de Chimie thérapeutique) Prize Session |
| ATHENA AUDITORIUM |
| 16:00 | Ceremony for the 2022 Galapagos Award for Drug Discovery Chemistry (in partnership with Société de Chimie thérapeutique) |
|
|
| Chairs |
Prof. Rebecca DEPREZ-POULAIN (INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)
Dr Alexis DENIS (GALAPAGOS, Ile de France, France) |
|
| 16:10 | GALAPAGOS AWARD LECTURE (Award-winning Team: Bioversys/University of Lille/GSK)
LE025 - Rejuvenating Ethionamide for Treatment of Tuberculosis - TRICky, but Possible |
Dr Modesto REMUINAN
(GSK, Tres Cantos (Madrid), Spain) |
|
|
Session 7
First Time Disclosures - Part 1 |
| ATHENA AUDITORIUM |
| 16:30 | Session Chair |
Dr Pilar MANZANO-CHINCHON
(GLAXOSMITHKLINE, Tres Cantos (Madrid), Spain) |
|
| 16:35 | LE026 - First-time Disclosure of M1069, a Highly Selective Dual Inhibitor of Adenosine A2a/A2b Receptors With Improved Therapeutic Activity Compared to A2a Receptor Selective Antagonists |
Dr Kai SCHIEMANN
(MERCK HEALTHCARE KGAA, Darmstadt, Germany) |
|
| 17:05 | LE027 - Discovery of BI 456906, a Novel Long-acting GCG/GLP-1 Receptor Dual Agonist for the Treatment of Patients With Obesity |
Dr Peter HAEBEL
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach Riss, Germany) |
|
| 17:35 | LE028 - Discovery of AZD5462, an Oral Agonist of the Relaxin Family Peptide Receptor 1 (RXFP1) for the Treatment of Cardiorenal Disease |
Dr Kenneth GRANBERG
(ASTRAZENECA, Mölndal, Sweden) |
|
|
| 18:05 | Poster Session 1 & Networking |
|
| AGORA HALL |
| 19:35 | End of the Day |
|
| Tuesday September 6, 2022 |
| 08:30 | PROUS INSTITUTE - OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
AL003 - How PROTACs Work: Molecular Recognition and Design Principles |
Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom) |
| ATHENA AUDITORIUM |
| 08:30 | Chair |
Dr Josep Jr. PROUS
(PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, Barcelona, Spain) |
| 09:15 | PL002 - The Shape and Modification of RNA in Health and Disease |
Prof. Eric MISKA
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
| 09:15 | Chair |
Dr Maria DUCA
(UNIVERSITY OF CÔTE D'AZUR, Nice, France) |
| 10:00 | Exhibition & Coffee |
|
| RHODES HALL |
Session 8 'Chemical Biology'
Addressing Cooperative Ligand Binding in Drug Discovery / EUCHEMS Session
| Session 9 'Drug Discovery'
Time to Act Against Antimicrobial Resistance
| Session 10 'Technologies'
New Screening Technologies : Affinity Selection - Mass Spectrometry |
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 10:30 | Session Chair |
Prof. Luc BRUNSVELD
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands) |
|
| 10:30 | Session Chair |
Prof. Maria-Jesus PÉREZ-PÉREZ
(INSTITUTO DE QUÍMICA MÉDICA, Madrid, Spain) |
|
| 10:30 | Session Chair |
Dr Didier ROCHE
(EDELRIS, Lyon, France) |
|
| 10:35 | LE029 - Fragment-Based Approaches to Stabilize Protein-Protein Interactions |
Prof. Michelle ARKIN
(UNIVERSITY OF CALIFORNIA, San Francisco, CA, United States) |
|
| 10:35 | LE033 - The Global Antibiotic R&D Partnership: Helping to Advance the Discovery & Development of New Treatments for Bacterial Infections |
Dr Benjamin BLASCO
(THE GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP (GARDP) , Geneva, Switzerland) |
|
| 10:35 | LE037 - Adapting the Affinity MS Technology to GPCR Ligand Discovery
Virtual Presentation |
Prof. Wenqing SHUI
(SHANGHAITECH UNIVERSITY, Shanghai, China) |
|
| 11:15 | LE030 - Development of Bisubstrate Inhibitors to Tackle Epigenetics |
Dr Paola B. ARIMONDO
(INSTITUT PASTEUR - CNRS, Paris, France) |
|
| 11:15 | LE034 - Novel Tetrazole Inhibitor of Mycobacterium Tuberculosis Tryptophan Synthase |
Dr Lourdes ENCINAS
(GLAXOSMITHKLINE, Madrid, Spain) |
|
| 11:15 | LE038 - EDELRIS Keymical Space™ and GPCR : Identification of Allosteric Binders by AS-MS |
Dr Renaud PRUDENT
(EDELRIS, Lyon, France) |
|
| 11:35 | LE031 - Identification and Structure-activity Relationship Profiling of Positive Allosteric Modulators Targeting Muscarinic Acetylcholine Receptors |
Dr Manuela JORG
(MONASH UNIVERSITY, Parkville, Australia) |
|
| 11:35 | LE035 - Discovery and Preclinical Development of ANT3310, a Broad-Spectrum β-Lactamase Inhibitor which Potentiates Meropenem Against Carbapenem-Resistant Bacteria |
Dr David DAVIES
(ANTABIO SAS, Labège, France) |
|
| 11:35 | LE039 - High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Intractable Targets |
Dr Jarrod WALSH
(ASTRAZENECA, Macclesfield, United Kingdom) |
|
| 11:55 | LE032 - Molecular Glues for the 14-3-3 Interactome |
Dr Richard DOVESTON
(UNIVERSITY OF LEICESTER, Leicester, United Kingdom) |
|
| 11:55 | LE036 - Discovery of Pseudomonas Aeruginosa Elastase LasB Inhibitors by in Situ Click Chemistry |
Dr Virgyl CAMBERLEIN
(HIPS - HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND, Saarbrücken, Germany) |
|
| 11:55 | LE040 - Accelerating Drug Discovery with the Integration of Affinity Selection Mass Spectrometry (ALIS) |
Mr Bryan CHOI
(RELAY THERAPEUTICS, Cambridge, United States) |
|
|
| 12:15 | Exhibition & Lunch |
|
| RHODES HALL |
| 12:15 | WuXi AppTec workshop
Introduction to Self-Service DNA-Encoded
libraries (DELs) |
|
| ROOM RISSO 6 |
| 12:15 | Chemical Computing Group workshop
De Novo Design of Novel Compounds to Meet
Multiple Property Constraints |
|
| ROOM RISSO 8 |
Flash Poster Session 4
FP31 to FP40
Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here
RHODES12 AUDITORIUM | Flash Poster Session 5
FP41 to FP50
Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here
ATHENA AUDITORIUM | Flash Poster Session 6
FP51 to FP60
Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here
HERMES AUDITORIUM |
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
|
|
|
|
|
Session 11 'Chemical Biology'
Targeting Self-Associating Proteins & Biomolecular Condensates in Drug Discovery | Session 12 'Drug Discovery'
Covalent Drugs
| Session 13 'Technologies'
Next Generation Medicinal Chemistry - an EFMC² Session |
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 13:45 | Session Chair |
Prof. Raphaël FREDERICK
(UCLOUVAIN, Brussels-Woluwe, Belgium) |
|
| 13:45 | Session Chair |
Dr Samir JEGHAM
(SANOFI R&D, Montpellier, France) |
|
| 13:45 | Session Chair |
Dr Clara CHRIST
(BAYER, Berlin, Germany) |
|
| 13:50 | LE041 - Targeting Protein-Protein Interactions of Receptor Complexes |
Prof. Kristian STROMGAARD
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark) |
|
| 13:50 | LE045 - Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib |
Dr Brian LANMAN
(AMGEN, Thousand Oaks, CA, United States) |
|
| 13:50 | Introduction to EFMC² |
Dr Richard LEWIS (NOVARTIS PHARMACEUTICALS, Basel, Switzerland)
Dr Franz VON NUSSBAUM (NUVISAN, Berlin, Germany) |
|
| 14:30 | LE042 - Leveraging Biomolecular Condensates for Drug Discovery |
Dr Marta FRIGOLE-VIVAS
(DEWPOINT THERAPEUTICS GMBH, Dresden, Germany) |
|
| 14:30 | LE046 - Covalent Fragment Approaches in Drug Discovery |
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary) |
|
| 14:00 | LE049 - Driving Lead Optimization with BRADSHAW |
Dr Darren GREEN
(GSK, Stevenage, United Kingdom) |
|
| 14:50 | LE043 - Polarity-sensitive Fluorescent Probes for Cellular Organelles: from Chemical to Genetically Encoded Targeting |
Dr Andrey KLYMCHENKO
(UNIVERSITÉ DE STRASBOURG, Illkirch, France) |
|
| 14:50 | LE047 - Discovery of Covalent Protein Kinase Inhibitors Targeting Cysteines in the Hinge Region |
Prof. Matthias GEHRINGER
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany) |
|
| 14:30 | LE050 - A Perspective on AI and Automation for the Medicinal Chemistry Lab
Virtual Presentation |
Prof. Connor COLEY
(MIT, Cambridge, United States) |
|
| 15:10 | LE044 - Interrogating Lactate Dehydrogenases Oligomeric Interfaces Using (Stapled) Peptides And Small Molecules |
Dr Léopold THABAULT
(INSTITUTE OF CANCER RESEARCH, London, United Kingdom) |
|
| 15:10 | LE048 - Discovery of Novel Covalent, EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of Her2 Exon 20 Insertion Driven Tumours |
Dr Birgit WILDING
(BOEHRINGER INGELHEIM, Vienna, Austria) |
|
| 14:50 | LE051 - The Power and Pitfalls of Machine Learning in Early Stage Drug Discovery |
Prof. Charlotte DEANE
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
| |
|
|
| 15:10 | LE052 - Using AI to Derive Valuable Insights from Drug Discovery Data |
Dr Matthew SEGALL
(OPTIBRIUM, Cambridge, United Kingdom) |
|
|
| 15:30 | Exhibition & Coffee |
|
| RHODES HALL |
Session 14
First Time Disclosures -Part 2 |
| ATHENA AUDITORIUM |
| 16:00 | Session Chair |
Dr Leena OTSOMAA
(ORION PHARMA, Espoo, Finland) |
|
| 16:05 | LE053 - mPGES1 Inhibitors: First Time Disclosure of Clinical Candidate BI01029539 / GS-248 |
Dr Roland PFAU
(BOEHRINGER INGELHEIM PHARMA GMBH&CO. KG, Ingelheim am Rhein, Germany) |
|
| 16:35 | LE054 - First Disclosure of Cannabinoid Receptor Type 2 Agonist Rg7774 – An Innovative Oral Treatment for Diabetic Retinopathy |
Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
|
| 17:05 | LE055 - Discovery and Optimisation of Potent, Slow-dissociating Inhaled PI4KB Inhibitors |
Dr Sophie BERTRAND
(GSK, Stevenage, United Kingdom) |
|
| 17:35 | LE103 - Discovery of a Selective Oral CCR4 Antagonist RPT193 for Treatment of Atopic Dermatitis and other Allergic Disorders |
Dr Mikhail ZIBINSKY
(RAPT THERAPEUTICS, INC., South San Francisco, United States) |
|
|
| 18:05 | Poster Session 2 & Networking |
|
| AGORA HALL |
| 19:35 | End of the Day |
|
| Wednesday September 7, 2022 |
| 08:30 | PL003 - Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire |
Prof. Sarah E. REISMAN
(CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States) |
| ATHENA AUDITORIUM |
| Chair |
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland) |
| 09:15 | EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry
Ceremony & Lectures |
|
| Chair |
Prof. Rui MOREIRA
(UNIVERSITY OF LISBON, Lisbon, Portugal) |
| 09:20 | EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN INDUSTRY
PR002 - Chemical Biology Strategies Applied to Phenotypic Screening and Targeted Protein Degradation Discovery Programs |
Dr Marie-Helene LARRAUFIE
(ALMIRALL, Barcelona, Spain) |
| 09:40 | EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN ACADEMIA
PR003 - Chemical Biology Tools for Enlightening Drug Discovery |
Prof. Olalla VÁZQUEZ
(PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany) |
| 10:00 | Exhibition & Coffee |
|
| RHODES HALL |
Session 15 'Chemical Biology'
In vivo Chemistry to Study Biological Mechanisms and to Develop Innovative Tools for Therapy and Diagnosis | Session 16 'Drug Discovery'
Rising Horizons of Small Molecule Immunotherapies and Beyond
| Session 17 'Technologies'
Innovative Synthetic Technologies for Drug Discovery
|
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 10:30 | Session Chair |
Dr Frédéric TARAN
(CEA/SACLAY, Gif-sur-Yvette, France) |
|
| 10:30 | Session Chair |
Prof. Antonio MACCHIARULO
(UNIVERSITY OF PERUGIA, Perugia, Italy) |
|
| 10:30 | Session Chair |
Dr Cara BROCKLEHURST
(NOVARTIS, Basel, Switzerland) |
|
| 10:35 | LE056 - Chemically-Triggered Payload Release in-vivo |
Dr Marc ROBILLARD
(TAGWORKS PHARMACEUTICALS, Eindhoven, The Netherlands) |
|
| 10:35 | LE060 - Tipping the Balance: MALT1 Inhibitors with Paradoxical Effects on the Immune System |
Dr Jean QUANCARD
(NOVARTIS, Basel, Switzerland) |
|
|
| 11:15 | LE057 - Tumor Activated Therapy |
Prof. Sebastien PAPOT
(UNIVERSITY OF POITIERS, Poitiers, France) |
|
| 11:15 | LE061 - The discovery of the Clinical Candidate AZD0284, a Orally Bioavailable Inverse Agonist of RORG for the Treatment of Psoriasis |
Dr Frank NARJES
(ASTRAZENECA, Gothenburg, Sweden) |
|
| 11:15 | LE065 - Photocatalysis in Drug Discovery |
Dr Lisa CANDISH
(BAYER, Wuppertal, Germany) |
|
| 11:35 | LE058 - Investigating and Controlling mRNAs Via Chemo-enzymatic Modification |
Prof. Andrea RENTMEISTER
(UNIVERSITY OF MÜNSTER, Münster, Germany) |
|
| 11:35 | LE062 - Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction |
Dr Dijana PESIC
(SELVITA, Zagreb, Croatia) |
|
| 11:35 | LE066 - Visible-light Photocatalysis: a Powerful Tool in the Pursuit of New Pharmaceuticals |
Dr Giulia BERGONZINI
(ASTRAZENECA, Gothenburg, Sweden) |
|
| 11:55 | LE059 - Fast Detection and Imaging of Hydrogen Peroxide with New Borinic Probes |
Dr Boris VAUZEILLES
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France) |
|
| 11:55 | LE063 - NR2F6 Antagonists: in Vitro Pharmacology and Preclinical Data of a Potential Next Generation Immuno-oncology Therapy |
Dr Francesco GRECO
(TES PHARMA SRL, Corciano, Italy) |
|
| 11:55 | LE067 - Iridium-catalyzed C-H Activation Methods for Late-stage Functionalization of Pharmaceuticals |
Dr Erik WEIS
(ASTRAZENECA, Mölndal, Sweden) |
|
|
| 12:15 | Exhibition & Lunch |
|
| RHODES HALL |
Session 18
Highlights in Medicinal Chemistry
Part 1 | Session 19 'Drug Discovery'
Targeting RNA by Small Molecules
Session Sponsored by Sanofi
| Session 20 'Technologies'
AI in Drug Discovery / CPA Session
|
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 13:15 | Session Chair |
Dr Jan Willem THURING
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium) |
|
| 13:15 | Session Chair |
Dr Hasane RATNI
(SKYHAWK THERAPEUTICS, Basel , Switzerland) |
|
| 13:15 | Session Chair |
Prof. Mingyue ZHENG
(SHANGHAI INSTITUTE OF MATERIA MEDICA, Shanghai, China) |
|
| 13:20 | LE068 - Formulation Strategies for Compounds with Challenging Physicochemical Properties |
Prof. Guy VAN DEN MOOTER
(KULEUVEN, Leuven, Belgium) |
|
| 13:20 | LE072 - Enabling Technologies for Revealing Druggable Paths in RNA Biology |
Dr Amanda GARNER
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States) |
|
| 13:20 | LE076 - Uncertainty Quantification: Considering the Reliability of Artificial Intelligence in Drug Design
Virtual Presentation |
Dr Dingyan WANG
(SHANGHAI INSTITUTE OF MATERIA MEDICA, Shanghai, China) |
|
| 14:00 | LE069 - Dual Inhibition of P53-MDM2/4 Interactions With Spiropyrazoline Oxindoles |
Ms Elizabeth A. LOPES
(UNIVERSITY OF LISBON, Lisboa, Portugal) |
|
| 14:00 | LE073 - Targeting RNA with Small Molecules, A New Therapeutic Strategy |
Dr Yann FORICHER
(SANOFI, Vitry-sur-Seine, France) |
|
| 14:00 | LE077 - Innovative Therapeutic Target Discovery based on OMIC Technology and Machine Learning
Virtual Presentation |
Prof. Feng ZHU
(ZHEJIANG UNIVERSITY, Hangzhou, China) |
|
| 14:20 | LE070 - Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106 |
Dr Timo HEINRICH
(MERCK, DARMSTADT, Germany) |
|
| 14:20 | LE074 - Fundamental Basis for SMN2 Specific Splicing Correction by Small Molecules and Bulge Repair Mechanism |
Dr Sébastien CAMPAGNE
(INSERM BORDEAUX, BORDEAUX, France) |
|
| 14:20 | LE078 - Opportunity and Challenge of Artificial Intelligence (AI) in Drug Delivery
Virtual Presentation |
Prof. Defang OUYANG
(MACAU UNIVERSITY, Macau, China) |
|
| 14:40 | LE071 - A New Dual Mode of Action to Treat Pain - From Scratch to Pre-Clinical Candidate |
Dr Anita WEGERT
(SYMERES, Nijmegen, The Netherlands) |
|
| 14:40 | LE075 - Bis-3-chloropiperidines Targeting TAR RNA as a Novel Strategy to Impair the HIV-1 Nucleocapsid Protein |
Dr Alice SOSIC
(UNIVERSITY OF PADOVA, Padova, Italy) |
|
| 14:40 | LE079 - In Silico Prediction of Brain Penetration - High Accuracy Achieved |
Dr Herve GENESTE
(ABBVIE, Ludwigshafen, Germany) |
|
|
| 15:00 | End of the Day |
|
| 15:45 | Excursions |
|
| 20:00 | Banquet |
|
| Thursday September 8, 2022 |
Session 21 'Chemical Biology'
Mining the Phosphosignaling Networks
| Session 22 'Drug Discovery'
New Treatments for Current and Future Pandemics | Session 23
Highlights in Medicinal Chemistry
Part 2
|
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 08:30 | Session Chair |
Dr Nadia AHMAD
(CHARLES RIVER LABORATORIES, Harlow, United Kingdom) |
|
| 08:30 | Session Chair |
Prof. Ana MARTINEZ
(CSIC, Madrid, Spain) |
|
| 08:30 | Session Chair |
Prof. Roberto DI SANTO (SAPIENZA UNIVERSITY OF ROME, Rome, Italy)
(SANOFI-AVENTIS DEUTSCHLAND GMBH) |
|
| 08:35 | LE080 - The Phosphatase Family: a Widely Neglected Target Space for Small-Molecule Drug Discovery |
Dr Gerhard MÜLLER
(ANAVO THERAPEUTICS, Leiden, The Netherlands) |
|
| 08:35 | LE084 - Searching for Drugs against Pandemic Viruses |
Dr Carmen GIL
(CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC), Madrid, Spain) |
|
| 08:35 | IUPAC-RICHTER PRIZE 2022
PR004 - Drug Discovery in Academia: A Drug For Glioblastoma Multiforme |
Prof. Michael E. JUNG
(UCLA CHEMISTRY & BIOCHEMISTRY, Los Angeles, United States) |
|
| 09:15 | LE081 - A Novel Fragment-Based Ligand Design Tool : Application to Kinase Research |
Prof. Pascal BONNET
(UNIVERSITY OF ORLÉANS, Orléans, France) |
|
| 09:15 | LE085 - Addressing Current Challenges in Antiviral Therapies Against Emerging RNA Viruses |
Dr Karine ALVAREZ
(AIX-MARSEILLE UNIVERSITY, Marseille, France) |
|
| 09:15 | LE088 - Discovery of Clinical Candidate CHF-6366: a Super-soft Heterobifunctional Muscarinic Antagonist and β2-adrenoceptor Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases |
Dr Laura CARZANIGA
(CHIESI FARMACEUTICI SPA, PARMA, Italy) |
|
| 09:35 | LE082 - Protein Phosphatase 2A, a Druggable Tumor Suppressor for Cancer Therapy |
Prof. Jukka WESTERMARCK
(UNIVERSITY OF TURKU, Turku, Finland) |
|
| 09:35 | LE086 - Embrace Complexity: in Silico Polypharmacological Profiling to Repurpose Medicines and Design New Drugs |
Dr Andrea BECCARI
(DOMPÉ PHARMA, L'Aquila, Italy) |
|
| 09:35 | LE089 - Discovery of JNJ-1245, a Novel and Potent Fluoroallylamide Mcl-1 Inhibitor for the Treatment of Hematologic Malignancies |
Dr Soufyan JERHAOUI
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium) |
|
| 09:55 | LE083 - Mining the Leishmania Kinome |
Dr Exequiel PORTA
(DURHAM UNIVERSITY, Durham, United Kingdom) |
|
| 09:55 | LE087 - Human Dihydroorotate Dehydrogenase Inhibitor MEDS443: a Magic Bullet Against Coronaviruses |
Dr Stefano SAINAS
(UNIVERSITY OF TORINO, Torino, Italy) |
|
| 09:55 | LE090 - Structure-Guided Design of Foldamer-Based Inhibitors of Protein-Protein Interactions |
Dr Gilles GUICHARD
(UNIVERSITY OF BORDEAUX, CBMN, Bordeaux, France) |
|
|
| 10:15 | Exhibition & Coffee |
|
| RHODES HALL |
Session 24 'Chemical Biology'
Chemical Probes for Target Identification & Validation / EUFEPS Session | Session 25 'Drug Discovery'
Drug Discovery in Targeting Neurodegenerative Disorders / ACSMEDI Session | Session 26 'Technologies'
Radiochemistry / AFMC Session
|
| RHODES12 AUDITORIUM | ATHENA AUDITORIUM | HERMES AUDITORIUM |
| 10:45 | Session Chair |
Dr Joanna REDMOND
(FRANCIS CRICK INSTITUTE, London, United Kingdom) |
|
| 10:45 | Session Chair |
Prof. Rong HUANG
(PURDUE UNIVERSITY, West Lafayette, IN, United States) |
|
| 10:45 | Session Chair |
Prof. Sun CHOI
(EWHA WOMANS UNIVERSITY, Seoul, Korea, South) |
|
| 10:50 | LE091 - Chemical Probes and How to Find Them |
Dr Alex PAUTSCH
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany) |
|
| 10:50 | LE095 - Beyond Amyloid and Tau: Exploring Alternative Therapeutic Targets Using an Integrative Approach |
Prof. Daniel WATTERSON
(NORTHWESTERN UNIVERSITY, Chicago, United States) |
|
| 10:50 | LE099 - Radiotheragnostics from Bench-to-Bedside Virtual Presentation |
Prof. Roger SCHIBLI
(ETH ZURICH, Zürich, Switzerland) |
|
| 11:30 | LE092 - De Novo Cyclic Peptides as Chemical Tools to Explore Epigenetic Regulation |
(SANOFI-AVENTIS DEUTSCHLAND GMBH)
Dr Louise WALPORT (THE FRANCIS CRICK INSTITUTE, London, United Kingdom) |
|
| 11:30 | LE096 - Discovery of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Autism, Down Syndrome, and Brain Disorders with Defective NKCC1/KCC2 Ratio |
Dr Marco BORGOGNO
(IAMA THERAPEUTICS SRL, Genoa, Italy) |
|
| 11:30 | LE100 - Evaluation of Cancer Immunity and Development of Novel Radiolabeling Method with Astatin-211
Virtual Presentation |
Dr Mikako OGAWA
(HOKKAIDO UNIVERSITY, Sapporo, Japan) |
|
| 11:50 | LE093 - Chemical Probes for Targets in Lipid Signalling |
Prof. Eugen PROSCHAK
(GOETHE UNIVERSITY OF FRANKFURT, Frankfurt/Main, Germany) |
|
| 11:50 | LE097 - Selective Butyrylcholinesterase Inhibitors for Alleviating Symptoms of Dementia |
Dr Urban KOSAK
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
|
| 11:50 | LE101 - Medicinal Chemistry in the Development of Molecular Imaging Probes Targeting Prostate-Specific Membrane Antigen |
Prof. Youngjoo BYUN
(KOREA UNIVERSITY, Sejong, Korea, South) |
|
| 12:10 | LE094 - First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation |
Prof. Rebecca DEPREZ-POULAIN
(INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France) |
|
| 12:10 | LE098 - Modulation of TDP-43-pathy by Brain Penetrant Protein Kinase Inhibitors, a New Hope for ALS and Related Disorders |
Prof. Ana MARTINEZ
(CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain) |
|
| 12:10 | LE102 - Development of First PET Tracers for the Imaging of CD73 Expression in Triple-negative Breast Cancer |
Dr Anna JUNKER
(EUROPEAN INSTITUTE FOR MOLECULAR IMAGING, Muenster, Germany) |
|
|
| 12:30 | Closing Lecture |
|
| ATHENA AUDITORIUM |
| PL004 - Drivers of Innovation in Drug Discovery |
Prof. Outi VAARALA
(ORION CORPORATION, Espoo, Finland) |
| Chair |
Prof. Gianluca SBARDELLA
(UNIVERSITY OF SALERNO, Fisciano, Italy) |
| 13:15 | Closing Remarks, EFMC-YSN PhD Prizes, Poster Prizes & Welcome to EFMC-ISMC 2024 |
Dr Maria DUCA (UNIVERSITY OF CÔTE D'AZUR, Nice, France)
Prof. Rui MOREIRA (UNIVERSITY OF LISBON, Lisbon, Portugal)
Prof. Roberto DI SANTO (SAPIENZA UNIVERSITY OF ROME, Rome, Italy) |
|
